This document describes the scientific priorities of the Office of the Gene Technology Regulator (OGTR) over the next 3 years from 2024 to 2027.
Details of OGTR monitoring and compliance activities during the quarter ended 31 December 2023.
DIR178, DIR175, DIR155, DIR149, DIR139, DIR138, DIR127, DIR173, DIR157, DIR145, DIR143, DIR091, DIR066/2006, DIR062/2005 and DIR 158 annual reports.
Limited and controlled release of wheat genetically modified for increased tolerance to environmental stress
When organisations engage with the OGTR we require appropriate people to be assigned key contact roles. This guidance document outlines the relationship between contact roles and the authority expected when interacting with the OGTR.
This document provides a step by step guide on how to access the form to certify a facility in the OGTR's Online Services Portal.
This document provides a step by step guide on how to access the form to make changes to a certification in the OGTR's Online Services Portal.
Commercial supply of a genetically modified cholera vaccine, Vaxchora®
Use this form to apply for a suspension of a low- or high-level containment facility currently certified under the Guidelines for the Certification of Physical Containment Facilities issued under the Gene Technology Act 2000.
Use this form to apply for the lift of suspension of a low or high-level containment facility currently certified under the Guidelines for the Certification of Physical Containment Facilities issued under the Gene Technology Act 2000.